BoB@JPM: Brian Hilberdink, Boehringer Ingelheim
Episode
44 min
Read time
2 min
Topics
Productivity, Health & Wellness, Startups
AI-Generated Summary
Key Takeaways
- ✓Private company advantage: Boehringer Ingelheim invests over 27% of revenue into R&D — a figure nearly unprecedented at its scale — made possible by private ownership that removes quarterly earnings pressure. This structure allows sustained funding of disease awareness campaigns, like the $12 urine test initiative for chronic kidney disease, even during periods of lower margins.
- ✓Obesity market positioning: Rather than competing directly against Novo Nordisk and Eli Lilly, Boehringer frames its obesity entry around clinical inertia — fewer than 10% of the 100 million Americans living with obesity receive evidence-based pharmacological treatment. The strategy targets narrative shift toward metabolic health ahead of a 2027 market entry, with pivotal data releasing in 2026.
- ✓Early-stage deal strategy: Boehringer deliberately avoids bidding wars for late-stage Phase 2 assets, instead targeting preclinical and early-development compounds to fill its pipeline funnel. This approach, centered at the Ridgefield, Connecticut campus, reduces acquisition costs and allows Boehringer to define the clinical development pathway rather than inherit someone else's.
- ✓Launch failure root causes: Hilberdink identifies three primary reasons new drug launches miss projections: misestimating disease prevalence in rare conditions, inadequate patient access through insurance or cash-pay pathways, and underestimating entrenched competitor share-of-voice. Smaller company experience at LEO Pharma, where competitors outspent them 20-to-1, sharpened his segmentation and differentiation discipline.
- ✓AI implementation structure: Boehringer built a centralized AI innovation team that pilots tools across the enterprise rather than deploying AI business-unit by business-unit. The focus is real-time provider and patient data synthesis to enable mid-launch course corrections. The team operates on a fail-fast-or-scale model, with current results skewing toward scaling successful pilots.
What It Covers
Brian Hilberdink, president of US Human Pharma at Boehringer Ingelheim, discusses the company's commercial strategy across cardio-renal-metabolic, oncology, and obesity pipelines, drawing on 26 years at Novo Nordisk and a leadership role at LEO Pharma to position Boehringer as a commercial powerhouse alongside its established research identity.
Key Questions Answered
- •Private company advantage: Boehringer Ingelheim invests over 27% of revenue into R&D — a figure nearly unprecedented at its scale — made possible by private ownership that removes quarterly earnings pressure. This structure allows sustained funding of disease awareness campaigns, like the $12 urine test initiative for chronic kidney disease, even during periods of lower margins.
- •Obesity market positioning: Rather than competing directly against Novo Nordisk and Eli Lilly, Boehringer frames its obesity entry around clinical inertia — fewer than 10% of the 100 million Americans living with obesity receive evidence-based pharmacological treatment. The strategy targets narrative shift toward metabolic health ahead of a 2027 market entry, with pivotal data releasing in 2026.
- •Early-stage deal strategy: Boehringer deliberately avoids bidding wars for late-stage Phase 2 assets, instead targeting preclinical and early-development compounds to fill its pipeline funnel. This approach, centered at the Ridgefield, Connecticut campus, reduces acquisition costs and allows Boehringer to define the clinical development pathway rather than inherit someone else's.
- •Launch failure root causes: Hilberdink identifies three primary reasons new drug launches miss projections: misestimating disease prevalence in rare conditions, inadequate patient access through insurance or cash-pay pathways, and underestimating entrenched competitor share-of-voice. Smaller company experience at LEO Pharma, where competitors outspent them 20-to-1, sharpened his segmentation and differentiation discipline.
- •AI implementation structure: Boehringer built a centralized AI innovation team that pilots tools across the enterprise rather than deploying AI business-unit by business-unit. The focus is real-time provider and patient data synthesis to enable mid-launch course corrections. The team operates on a fail-fast-or-scale model, with current results skewing toward scaling successful pilots.
Notable Moment
Hilberdink revealed that zongoritinib (Harnexios), Boehringer's HER2-mutant non-small cell lung cancer drug, received an unsolicited FDA Commissioner's Priority Review Voucher — a designation the company never petitioned for — compressing the approval window to one to two months and accelerating first-line approval by roughly six months.
Episode Transcript
Welcome back to the Business of Biotech on location at the JPMorgan Healthcare Conference. I'm your host, Ben Comer, chief editor at Life Science Leader. And today, I'm speaking with Brian Hilberdijk, president of US Human Pharma at Boehringer Ingelheim, the world's largest the world's largest privately held biopharmaceutical company with development programs in cardio, renal, metabolic disease, CNS disease, immunology and respiratory diseases, oncology, and retinal health. Did I miss any, Brian? I I think you covered it. Okay. Brian is making his second appearance on the business of biotech. He spoke with the show's founding host, Matt Pillar, back in the 2023, and at that time was working to grow LeoPharma's presence in The United States as the lead of Leo's US operations. I'm looking forward to catching up with Brian today about his time at Leo and jump to Boehringer in February, what lessons and learnings he brings with him from Leo to Boehringer, his strategy for growing Boehringer's US business, and what issues or market dynamics he's monitoring in The US. Thank you so much for coming back on the show, Brian. Yeah. Thanks for having me, Dan. I'm excited to do this. Boehringer or Boehringer? Do you say it both ways? Think about Depending on if you're German and in Germany or in The US. I know it's a mouthful. Think burr like I'm cold. Uh-huh. Boehringer. Burringer. Yeah. Burringer. Burringer. Okay. Yeah. And I know for years in the industry, people just refer to us as BI. Yeah. But we're really trying to brand, and we're really proud of the history and heritage, so it's Burr. I've heard Boehringer and Boehringer, but not Boehringer. So now I have a a third, pronunciation, and it's that's the right one, it sounds like. So I'll, I'll do the best I can. Pretty sure. I'll do the best I can. I mentioned your previous role, Brian, at LeoPharma. But before that, you worked for twenty six years at Novo Nordisk, a Danish company that has done, fairly well in recent years with a product called semaglutide. Some folks listening may have heard of it. At the time you left, you were vice president of sales, following a transition of Novo Nordisk's commercial model. You joined LEO, another Danish company, as head of the US and as a member of the global executive team in 2023, I believe. Picking up perhaps where Matt, left off, what can you say about your experiences at Leo? You probably learned a lot about the dermatology segment for one thing. I did. LeoPharma is a focused medical dermatology company. And, also, interesting enough, a privately held company that goes all the way back to nineteen o eight. Not as old as Burrow, but a old historic company that actually made insulin on behalf of Novo Nordisk going back to 1923. So all those years at Novo, I knew about the history between Novo and LEO. And LEO was a company that was …
Get the full transcript (8,055 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 41-minute episode.
Get Business Of Biotech summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from Business Of Biotech
Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig
Sep 7 · 55 min
Biotech 2050 Podcast
Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier
Jan 28
More from Business Of Biotech
Picking Biotech Winners Beyond The Hype Cycle With Andera Partners' Olivier Litzka
Aug 31 · 58 min
In Good Company with Nicolai Tangen
XPeng Co-President: China's EV Race, Flying Cars and Humanoid Robots
Sep 10
More from Business Of Biotech
We summarize every new episode. Want them in your inbox?
Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig
Picking Biotech Winners Beyond The Hype Cycle With Andera Partners' Olivier Litzka
Biotech Investing At The Earliest Stages With Santé Ventures' Omar Khalil
Getting To A First Product Approval With Celcuity's Brian Sullivan
Cell Therapy Advances And Biotech Leadership With Nkarta's Paul Hastings
Similar Episodes
Related episodes from other podcasts
Biotech 2050 Podcast
Jan 28
Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier
In Good Company with Nicolai Tangen
Sep 10
XPeng Co-President: China's EV Race, Flying Cars and Humanoid Robots
Beyond Biotech
Jun 26
De-risking neurology drug development with better mouse models
The AI Breakdown
Aug 23
The Real Future of AI and Work
The Diary of a CEO
Aug 17
Top Scientist REVEALS: AI Could Be The Next Einstein, Robots Will Deserve Rights! | Prof Brian Greene
Explore Related Topics
This podcast is featured in Best Biotech Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Health & Longevity Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into Business Of Biotech.
Every Monday, we deliver AI summaries of the latest episodes from Business Of Biotech and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime